HIV broadly neutralizing antibodies (bNAbs) confer protection following passive immunization, but the immunological mechanisms that drive their development in a fraction of HIV infected individuals are poorly understood. Structural features of bNAbs indicate that they originate from extensive B cell germinal center reactions, which rely on immune complex (IC)-mediated delivery of antigen to follicular dendritic cells (FDCs). However, little is known about the role of immune complexes in tuning the evolution of bNAbs.
Here we characterized the HIV-specific antibody responses in a group of Neutralizers that neutralized 80% of 11 tier 2 viruses, and a matched group of Non-Neutralizers that exhibited no detectable neutralizing activity. Firstly, we applied a system serology Fc-profiling platform to determine Fc structural features that are associated with the development of Fab neutralizing activity. Then, we developed a new series of Fc-engineered immune complexes-based adjuvants and characterized their mechanisms of action in mouse vaccination studies.
We show that HIV-specific antibodies from Neutralizers mediate better antigen phagocytosis and complement deposition, bind better Fc-receptors and complement proteins, and are associated with increased functionality in mouse vaccination studies (Fig.1A). We than hypothesized that such functional differences were determined by structural modifications of the HIV-specific antibodies. Biophysical characterization of the antibody Fc of HIV-specific antibodies revealed that sialylated IgG1 antibodies were associated with the development of bNAbs (Fig.1B). Given the importance of antigen-antibody immune complexes in driving antibody Fab maturation, we rationally designed immune complex-based vaccines with IgG1 antibody glycoforms to use in mouse vaccination studies. Finally we show that sialylated IgG1 antibodies, in immune complexes with HIV gp120, work as adjuvants to promote enhanced antigen uptake from innate immune cells, expanded germinal centers and increase HIV-specific humoral responses as compared to non-sialylated IgG1 antibodies (Fig.1C-D).
This work supports a potentially critical adjuvanting role for specific glycosylated IC forms in promoting more effective B cell selection that may contribute to the rational design of neutralizing antibody-inducing vaccines against HIV.